Quantifying benefit-risk preferences for medical interventions: An overview of a growing empirical literature

Applied Health Economics and Health Policy

Volumn 11, Issue 4, 2013, Pages 319-329

  Brett Hauber, A ^a   Fairchild, Angelyn O ^a   Reed Johnson, F ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CONCEPTUAL FRAMEWORK; DECISION MAKING; EMPIRICISM; EVIDENCE BASED PRACTICE; HUMAN; MEDICAL DECISION MAKING; MEDICAL DEVICE; PROSTATE HYPERTROPHY; RATING SCALE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SYSTEMATIC REVIEW;

DELIVERY OF HEALTH CARE; DRUG THERAPY; RISK ASSESSMENT; UNITED STATES;

EID: 84880862732     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0028-y     Document Type: Review

References (50)

1. Cioms, IV Working Group. Benefit-risk balance for marketed drugs: evaluating safety signals. Report of the CIOMS Working Group IV. Geneva: Council for International Organizations of Medical Sciences; 1998.
2. Lynd L, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol. 2004;57(8):795-803. (Pubitemid 39370162)
3. Van Houtven G, Johnson FR, Kilambi V, Hauber AB. Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Making. 2011;31(3):469-80.
4. Ho M, Lavery B, Pullar T. The risk of treatment. A study of rheumatoid arthritis patients' attitudes. Br J Rheumatol. 1998;37(4):459-60.
5. Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease? Br J Rheumatol. 1990;29(3):215-8. (Pubitemid 20194026)
6. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer. 1995;31A(12):1955-9. (Pubitemid 26023084)
7. Barker JH, Furr A, Cunningham M, Grossi F, Vasilic D, Storey B, et al. Investigation of risk acceptance in facial transplantation. Plast Reconstr Surg. 2006;118(3):663-70.
8. Majzoub RK, Cunningham M, Grossi F, Maldonado C, Banis JC, Barker JH. Investigation of risk acceptance in hand transplantation. J Hand Surg Am. 2006;31(2):295-302. (Pubitemid 43227283)
9. Reynolds CC, Martinez SA, Furr A, Cunningham M, Bumpous JM, Lentsch EJ, et al. Risk acceptance in laryngeal transplantation. Laryngoscope. 2006;116(10):1770-5. (Pubitemid 44511359)
10. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323(7323):1218-22.
11. Kopec JA, Richardson CG, Llewellyn-Thomas H, Klinkhoff A, Carswell A, Chalmers A. Probabilistic threshold technique showed that patients' preferences for specific trade-offs between pain relief and each side effect of treatment in osteoarthritis varied. J Clin Epidemiol. 2007;60(9):929-38. (Pubitemid 47198453)
12. Richardson CG, Chalmers A, Llewellyn-Thomas HA, Klinkhoff A, Carswell A, Kopec JA. Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications. J Rheumatol. 2007;34(7):1569-75. (Pubitemid 47067997)
13. Llewellyn-Thomas HA, Arshinoff R, Bell M, Williams JI, Naylor CD. In the queue for total joint replacement: patients' perspectives on waiting times. Ontario Hip and Knee Replacement Project Team. J Eval Clin Pract. 1998;4(1):63-74. (Pubitemid 128504340)
14. Finlayson SR, Birkmeyer JD, Tosteson AN, Nease RF Jr. Patient preferences for location of care: implications for regionalization. Med Care. 1999;37(2):204-9.
15. Palda VA, Llewellyn-Thomas HA, Mackenzie RG, Pritchard KI, Naylor CD. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol. 1997;15(10):3192-200. (Pubitemid 27419331)
16. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making. 1996;16(3):262-82. (Pubitemid 26230578)
17. Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr. 2001;30:146-52.
18. Llewellyn-Thomas HA, Paterson JM, Carter JA, Basinski A, Myers MG, Hardacre GD, Dunn EV, D'Agostino RB, Naylor CD. Primary prevention drug therapy: can it meet patients' requirements for reduced risk? Med Decision Making. 2002;22:326-39. (Pubitemid 34791320)
19. O'Brien BJ, Elswood J, Calin A. Willingness to accept risk in the treatment of rheumatic disease. J Epidemiol Community Health. 1990;44(3):249-52. (Pubitemid 20327432)
20. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health. 1986;76(4):392-6. (Pubitemid 16066449)
21. Fraenkel L, Bodardus S, Wittnik DR. Understanding patient preferences for the treatment of lupus nephritis with adaptive conjoint analysis. Med Care. 2001;39(11):1203-16. (Pubitemid 33603665)
22. Sassi F, McKee M. Do clinicians always maximize patient outcomes? A conjoint analysis of preferences for carotid artery testing. J Health Serv Res Policy. 2008;13(2):61-6. (Pubitemid 351702968)
23. Johnson FR, Ozdemir S, Hauber B, Kauf TL. Women's willingness to accept perceived risks for vasomotor symptom relief. J Womens Health. 2007;16(7):1028-40. (Pubitemid 47479947)
24. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HA, Koes BW, Steyerberg EW. Patients' preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int. 2008;19(7):1029-37.
25. Eberth B, Watson V, Ryan M, Hughes J, Barnett G. Does one size fit all? Investigating heterogeneity in men's preferences for benign prostatic hyperplasia treatment using mixed logit analysis. Med Decis Making. 2009;29(6):707-15.
26. McTaggart-Cowan HM, Shi P, Fitzgerald JM, Anis AH, Kopec JA, Bai TR, et al. An evaluation of patients' willingness to trade symptom-free days for asthma-related treatment risks: a discrete choice experiment. J Asthma. 2008;45(8):630-8.
27. Salkeld G, Solomon M, Short L, Ryan M, Ward JE. Evidence-based consumer choice: a case study in colorectal cancer screening. Aust N Z J Public Health. 2003;27(4):449-55. (Pubitemid 37038228)
28. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133(3):769-79. (Pubitemid 47374126)
29. Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. Patient Educ Couns. 2007;65(2):237-44. (Pubitemid 46073565)
30. Hauber AB, Johnson FR, Grotzinger KM, Ozdemir S. Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. Ann Pharmacother. 2010;44(3):479-88.
31. Mohamed AF, Johnson FR, Hauber AB, Lescrauwaet B, Masterson A. Physicians' stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy. Eur J Gastroenterol Hepatol. 2012;24(4):419-26.
32. Lewis SM, Cullinane FN, Bishop AJ, Chitty LS, Marteau TM, Halliday JL. A comparison of Australian and UK obstetricians' and midwives' preferences for screening tests for down syndrome. Prenat Diagn. 2006;26(1):60-6. (Pubitemid 43189334)
33. Bridges JF, Mohamed AF, Finnern HW, Woehl A, Hauber AB. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012;77(1):224-31.
34. Hauber AB, Johnson FR, Fillit H, Mohamed AF, Leibman C, Arrighi HM, Grundman M, Townsend RJ. Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease. Alzheimer Dis Assoc Disord. 2009;23(1):23-32.
35. Johnson FR, Hauber AB, Ozdemir S, Lynd L. Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. Value Health. 2010;13(4):418-23.
36. Johnson FR, Hauber B, Ozdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm. 2010;16(8):616-28.
37. Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009;29(1):121-36.
38. Johnson FR, Van Houtven G, Ozdemir S, Hass S, White J, Francis G, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256(4):554-62.
39. Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011;29(11):977-88.
40. Wong MK, Mohamed AF, Hauber AB, Yang JC, Liu Z, Rogerio J, Garay CA. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ. 2012;15(6):1139-48.
41. Ratcliffe J, Buxton M. Patients' preferences regarding the process and outcomes of life-saving technology. An application of conjoint analysis to liver transplantation. Int J Technol Assess Health Care. 1999;15(2):340-51. (Pubitemid 29380444)
42. Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J. Patients' preferences for characteristics associated with treatments for osteoarthritis. Rheumatology (Oxford). 2004;43(3):337-45. (Pubitemid 38313184)
43. Arden NK, Hauber AB, Mohamed AF, Johnson FR, Peloso PM, Watson DJ, et al. How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom? J Rheumatol. 2012;39(5):1056-63.
44. Hauber AB, Mohamed AF, Watson ME, Johnson FR, Hernandez JE. Benefits, risk, and uncertainty: preferences of antiretroviral-naive African Americans for HIV treatments. AIDS Patient Care STDS. 2009;23(1):29-34.
45. European Medicines Agency (2010) Road map to 2015. http://www.ema.europa. eu/docs/en-GB/document-library/Report/2011/01/WC500101373.pdf. Accessed 15 April 2012.
46. Maxmen A. Law spurs regulator to heed patients' priorities. Nature. 2012;487(7406):154. doi: 10.1038/487154a.
47. Holden WL. Benefit-risk analysis: a brief review and proposed quantitative approaches. Drug Saf. 2003;26(12):853-62. (Pubitemid 37188248)
48. Lynd LD, Naiafzadeh M, Colley L, Byrne MF, Willan AR, Sculpher MJ, Johnson FR, Hauber AB. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision making - a case study of alosetron in irritable bowel syndrome. Value Health. 2010;13(4):411-7.
49. Glickman TS, Gough M. Readings in risk. Washington, DC: Resources for the Future; 1990.
50. Kahneman D, Tversky A. Choices, values, and frames. Oxford: Cambridge University Press; 2000.